- Home
- BMEA vs INUV Comparison
BMEA vs INUV Comparison
Compare BMEA & INUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- INUV
- Stock Information
- Founded
- BMEA 2017
- INUV N/A
- Country
- BMEA United States
- INUV United States
- Employees
- BMEA N/A
- INUV N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- INUV Advertising
- Sector
- BMEA Health Care
- INUV Consumer Discretionary
- Exchange
- BMEA Nasdaq
- INUV Nasdaq
- Market Cap
- BMEA 65.8M
- INUV 75.7M
- IPO Year
- BMEA 2021
- INUV N/A
- Fundamental
- Price
- BMEA $1.57
- INUV $4.86
- Analyst Decision
- BMEA Strong Buy
- INUV Strong Buy
- Analyst Count
- BMEA 10
- INUV 2
- Target Price
- BMEA $21.00
- INUV $17.50
- AVG Volume (30 Days)
- BMEA 957.5K
- INUV 128.2K
- Earning Date
- BMEA 08-12-2025
- INUV 08-07-2025
- Dividend Yield
- BMEA N/A
- INUV N/A
- EPS Growth
- BMEA N/A
- INUV N/A
- EPS
- BMEA N/A
- INUV N/A
- Revenue
- BMEA N/A
- INUV $93,478,114.00
- Revenue This Year
- BMEA N/A
- INUV $30.46
- Revenue Next Year
- BMEA N/A
- INUV $12.29
- P/E Ratio
- BMEA N/A
- INUV N/A
- Revenue Growth
- BMEA N/A
- INUV 18.20
- 52 Week Low
- BMEA $1.29
- INUV $1.90
- 52 Week High
- BMEA $13.07
- INUV $7.90
- Technical
- Relative Strength Index (RSI)
- BMEA 37.40
- INUV 46.30
- Support Level
- BMEA $1.72
- INUV $4.82
- Resistance Level
- BMEA $1.75
- INUV $5.34
- Average True Range (ATR)
- BMEA 0.11
- INUV 0.47
- MACD
- BMEA -0.02
- INUV -0.13
- Stochastic Oscillator
- BMEA 9.20
- INUV 12.96
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About INUV Inuvo Inc.
Inuvo Inc develops and sells information technology solutions for marketing. It develops technology to deliver content and targeted advertisements over the internet. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.